Interpretation of Clinical Practice Guidelines for Management of Kidney Injury During Anticancer Drug Therapy 2022 (Ⅳ): dose adjustment of anticancer drug in patients with impaired kidney function (Part 1)
10.3760/cma.j.cn114015-20240603-00413
- VernacularTitle:《抗肿瘤药物治疗期间肾损伤管理临床实践指南（2022）》解读（四）：肾损伤患者抗肿瘤药物的剂量调整（第1部分）
- Author:
Zhe CHEN
1
;
Xizi ZHENG
;
Qingqing ZHOU
;
Guohui LI
Author Information
1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院药剂科，北京 100021
- Publication Type:Journal Article
- Keywords:
Antineoplastic agents;
Renal insufficiency, chronic;
Chronic kidney disease;
Drug dose adjustment;
Guideline;
Interpretation
- From:
Adverse Drug Reactions Journal
2024;26(8):449-453
- CountryChina
- Language:Chinese
-
Abstract:
Accumulation of drugs and its metabolites in the body occurs and risks of adverse drug reactions increase in renal insufficiency patients due to the renal function decline or delay of renal excretion and the pharmacokinetic changes related to the decline of renal function. Therefore, the dose of anticancer drugs should be adjusted in tumor patients with renal dysfunction. The Japanese Society of Nephrology, Japan Society of Clinical Oncology, Japanese Society of Medical Oncology, and Japanese Society of Nephrology and Pharmacotherapy have jointly formulated Clinical Practice Guidelines for Management of Kidney Injury During Anticancer Drug Therapy 2022, and specifically discusses the dose adjustment of anticancer drug for patients with renal injury in the second chapter. This article focuses on the interpretation of the principle of drug dose adjustment for patients with renal insufficiency and suggestions for dose adjustment of platinum drugs and fluorouracil drugs in this chapter.
